Launch of the EHVA consortia funded by the EU H2020 program
27 January 2016
Start of the EV02 trial in Lausanne and London
16 February 2005
EuroVacc started the phase I trial (EV02) in Lausanne and London to evaluate the safety of DNA-HIV-C alone and of the prime-boost regimen of DNA-HIV-C+NYVAC-HIV-C, and to compare the immunogenicity of the prime-boost regimen to NYVAC-HIV-C alone in healthy volunteers at low risk of acquiring HIV infection.